Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Neuraxis Inc (NRXS)
AMEXHealth CareBiotechnologySnapshot 2026-11-05
$6.11-10.93%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NRXS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain cash and equivalents near $7.1M in 2026-Q1 | Cash reserves are about $7.1M to support operations. | Intact | cash falls below $5 million in 2026-Q1 | Cash and cash equivalents: $8.322M FY2026-Q2; GAAP. Published target: >= $7.1 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Date unavailable8,322,258 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
NRXS is a speculative growth business, not yet a profitable compounder. The long-term thesis is in a watch state: revenue is growing, but recent financial performance remains below its industry cohort and the evidence points to high risk.
NRXS carries a durable premium to peers, meaning the market valuation is higher than peer levels, despite ongoing losses. The evidence does not show fragile pricing signals, but it also does not specify what growth or profitability expectations are already reflected in that premium.
Near term, revenue growth has tracked management’s stated priority, rising from $0.9 million in 2025-Q1 to $1.93 million in 2026-Q2. Loss control is behind: operating losses widened from $1.74 million to $2.12 million between 2026-Q1 and Q2, while cash reserves remain a concern amid past operating cash outflows. The next guidance update and the weaker jobs trend are risks; the miss-risk estimate is 35%, though its watch tier is quiet.
The multi-year thesis hinges on revenue growth continuing and operating losses becoming more manageable without weakening cash reserves. Near term, a guidance cut or further weakening in jobs data would pressure the setup, while continued strong results and guidance from healthcare bellwethers could support the sector backdrop.
Over the next 1 to 3 years, NRXS remains a high-risk growth story with improving revenue but unresolved losses and a premium valuation. The thesis is still in watch status, with execution and the healthcare backdrop as key swing factors. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 5 quarters. The Company reported expected cash reserves of approximately $7.1 million as of 2026-Q1, with negative cash from operations in prior quarters. The trajectory shows ongoing efforts to maintain liquidity amid operating cash outflows.
Reduce operating losses below $1.7M in 2026-Q1 | A primary condition in Neuraxis Inc's published investment case. The stated target is <= -$1.7 million. | Under Pressure | operating loss worsens beyond -$2.1 million in 2026-Q1 | Operating income: $-2.125M FY2026-Q2; GAAP. Published target: <= -$1.7 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 11, 2026-2,124,712 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 5 of last 5 quarters. Operating losses increased from negative $1.74 million in 2026-Q1 to negative $2.12 million in 2026-Q2, indicating limited progress in managing operating losses despite ongoing focus. Delivery assessment Oct 31, 2026 |
Increase revenue to at least $1.6M in 2026-Q1 | A primary condition in Neuraxis Inc's published investment case. The stated target is >= $1.6 million. | Intact | revenue falls below $1.0 million in 2026-Q1 | Revenue: $1.929M FY2026-Q2; GAAP. Published target: >= $1.6 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 11, 20261,928,695 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 5 of last 5 quarters. Revenue grew from $0.9 million in 2025-Q1 to $1.93 million in 2026-Q2, with guidance for $1.6 million in 2026-Q1. The trajectory shows delivering revenue growth consistent with management's stated priority. Delivery assessment Oct 31, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.06 → $-0.27 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-07-25 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-07-26 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-07-27 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-07-28 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-07-29 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-07-30 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-07-31 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-01 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-02 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-03 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-04 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-05 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-06 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-07 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-08 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-09 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-10 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-12 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-13 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-14 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-15 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-16 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-17 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-18 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-19 | $-0.06 | $20,700,000 | 1 / 1 |
| 2026-08-20 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-08-21 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-08-22 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-08-23 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-08-24 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-08-25 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-08-26 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-08-27 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-08-28 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-08-29 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-08-30 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-08-31 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-01 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-02 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-03 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-04 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-05 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-06 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-07 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-08 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-09 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-10 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-11 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-12 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-13 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-14 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-15 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-16 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-17 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-18 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-19 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-20 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-21 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-22 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-23 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-24 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-25 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-26 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-27 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-28 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-29 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-09-30 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-01 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-02 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-03 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-04 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-05 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-06 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-07 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-08 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-09 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-10 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-11 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-12 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-13 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-14 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-15 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-16 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-17 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-18 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-19 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-20 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-21 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-22 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-23 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-24 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-25 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-26 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-27 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-28 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-29 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-30 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-10-31 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-11-01 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-11-02 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-11-03 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-11-04 | $-0.27 | $19,800,000 | 1 / 1 |
| 2026-11-05 | $-0.27 | $19,800,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.